The Aporia
What to know about new GLP-1 warning on possible vision loss. (2026, November 10). CBS News. https://www.cbsnews.com/video/what-to-know-about-new-glp-1-warning-on-possible-vision-loss/
“What to know about new GLP-1 warning on possible vision loss.” CBS News, 10 Nov. 2026, https://www.cbsnews.com/video/what-to-know-about-new-glp-1-warning-on-possible-vision-loss/.
“What to know about new GLP-1 warning on possible vision loss.” CBS News, November 10, 2026. https://www.cbsnews.com/video/what-to-know-about-new-glp-1-warning-on-possible-vision-loss/.
Dated from the outlet's own feed. Check the original for its byline.
The U.S. Food and Drug Administration (FDA) has ordered makers of popular weight-loss GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound to add warnings about a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can cause sudden and permanent vision loss. The FDA announced on November 9, 2026, that the new warning follows research linking GLP-1 drugs to an increased risk of NAION, where patients may experience painless vision loss in one eye upon waking. This condition affects the optic nerve and can result in significant vision impairment or blindness. While some studies indicate a potential link between these drugs and NAION, more research is needed to fully understand the relationship, especially considering that many patients with risk factors for NAION might already have conditions like diabetes or obesity before starting GLP-1 therapy.
8 outlets covered “FDA Warns GLP-1 Drugs Eye Risk”.
One AI summary per outlet of its latest article on this story, written from that article alone and checked against it. Open the article for the outlet's own words.
The FDA has announced that GLP-1 drugs will include warnings about a rare side effect that could result in vision loss. Dr. Rachel Pessah-Pollack is interviewed by CBS News to provide more details on this development.
GLP-1 drugs to carry warning about rare vision-loss side effect, FDA says →4 articles from CBS News on this storyThe U.S. Food and Drug Administration has required manufacturers of weight-loss drugs like Ozempic and Wegovy to include warnings about a rare eye condition called NAION that can lead to permanent vision loss. The FDA’s decision, made after reviewing reports from over 134,000 patients, found an increased risk of six cases per 100,000 people annually for those taking GLP-1 drugs compared to about four cases among…
Weight loss drugs linked to new rare side effect as new warning labels required →2 articles from The Independent on this storyThe Food and Drug Administration has mandated that manufacturers of GLP-1 drugs, such as Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound, include warnings about a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION) which can cause sudden blindness. This decision follows research indicating an increased risk of NAION in patients using GLP-1 medications…
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness →The FDA has mandated that manufacturers update warning labels on GLP-1 drugs like Ozempic and Wegovy to include a potential risk of nonarteritic anterior ischemic optic neuropathy (NAION), an eye condition that can lead to permanent vision loss or blindness. This decision follows a study showing diabetes patients taking semaglutide are four times more likely to develop NAION compared to those not using the drug…
GLP-1 drugs must have new warning label over incurable blindness condition, says FDA →The Food and Drug Administration will require weight loss drugs like Ozempic and Wegovy to include warnings about a rare side effect that can lead to permanent vision loss due to non-arteritic anterior ischemic optic neuropathy. This condition, which has been reported with all GLP-1 drugs used for obesity and diabetes management, can result in significant vision impairment. The FDA initiated this review following a…
Weight loss drugs, such as Ozempic, to carry FDA warning about rare vision-loss side effects →The FDA announced on Monday that it will require drug labels for GLP-1 medications, including Ozempic and Wegovy, to include a warning about the rare but serious risk of non-arteritic anterior ischemic optic neuropathy (NAION), which can lead to permanent vision loss. Based on an analysis of over 125 clinical trials, the condition occurs in approximately six out of every 100,000 patients using GLP-1 drugs for at…
FDA to require vision loss warning on GLP-1 drug labels →The US FDA has issued a warning about GLP-1 weight loss medications, including Novo Nordisk’s Ozempic and Wegovy, Eli Lilly’s Mounjaro and Zepbound, and Sanofi’s Soliqua, due to the risk of nonarteritic anterior ischemic optic neuropathy (NAION), which can cause sudden blindness. The FDA reviewed 126 clinical trials involving over 134,200 patients and found a higher incidence rate of NAION in GLP-1 users compared to…
FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications →The FDA has instructed manufacturers of GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound to include warnings about a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can cause sudden blindness. NAION occurs when blood vessels supplying the optic nerve are blocked, leading to vision loss that may be permanent. The FDA’s decision is based on its review of reports and…
Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness →How the first headlines put it
GLP-1 drugs must have new warning label over incurable blindness condition, says FDA
US is requiring weight-loss drug makers to warn about possible loss of eye sight
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
FDA warns of rare vision-loss side effect from GLP-1 drugs
